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Background: To report our experience with increased dose intensity-modulated radiation and concurrent systemic
chemotherapy as definitive treatment of locally advanced esophageal cancer.
Patients and methods: We analyzed 27 consecutive patients with histologically proven esophageal cancer, who
were treated with increased-dose IMRT as part of their definitive therapy. The majority of patients had T3/4 and/or
N1 disease (93%). Squamous cell carcinoma was the dominating histology (81%). IMRT was delivered in step-and-shoot
technique in all patients using an integrated boost concept. The boost volume was covered with total doses of 56-60
Gy (single dose 2-2.14 Gy), while regional nodal regions received 50.4 Gy (single dose 1.8 Gy) in 28 fractions. Concurrent
systemic therapy was scheduled in all patients and administered in 26 (96%). 17 patients received additional adjuvant
systemic therapy. Loco-regional control, progression-free and overall survival as well as acute and late toxicities were
retrospectively analyzed. In addition, quality of life was prospectively assessed according to the EORTC QLQs (QLQ-OG25,
QLQ-H&N35 and QLQ-C30).
Results: Radiotherapy was completed as planned in all but one patient (96%), and 21 patients received more than 80%
of the planned concurrent systemic therapy. We observed ten locoregional failures, transferring into actuarial 1-, 2- and
3-year-locoregional control rates of 77%, 65% and 48%. Seven patients developed distant metastases, mainly to the lung
(71%). The actuarial 1-, 2- and 3-year-disease free survival rates were 58%, 48% and 36%, and overall survival rates were
82%, 61% and 56%. The concept was well tolerated, both in the clinical objective examination and also according to the
subjective answers to the QLQ questionnaire. 14 patients (52%) suffered from at least one acute CTC grade 3/4 toxicity,
mostly hematological side effects or dysphagia. Severe late toxicities were reported in 6 patients (22%), mostly esophageal
strictures and ulcerations. Severe side effects to skin, lung and heart were rare.
Conclusion: IMRT with concurrent systemic therapy in the definitive treatment of esophageal cancer using an integrated
boost concept with doses up to 60 Gy is feasible and yields good results with acceptable acute and late overall toxicity
and low side effects to skin, lung and heart.
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Table 1 Patient characteristics
Patient characteristics n % n %
Age Histology
median 63 squamous cell 22 81
min 42 adeno 3 11
max 79 other 2 7
Gender cN stage
male 22 81 0 7 26
female 5 19 1 20 74
Localisation cT stage
cervical 4 15 1 1 4
upper thoracic 7 26 2 3 11
central thoracic 10 37 3 21 78
lower thoracic 6 22 4 2 7
Dose to PTV1 [Gy] Dose to PTV2 [Gy]
median 56 median 50.4
min 19.2 min 14.4
max 62 max 52.2
≥ 56 Gy 26 96 ≥ 50.4 Gy 24 89
simultaneous CHT adjuvant CHT
yes 26 96 yes 17 63
no 1 4 no 10 37
n: number of patients,%: percentage, PTV: planning target volume; Gy: Gray,
min: minimum; max: maximum, CHT: chemotherapy, cN: clinical N stage, cT:
clinical T stage.
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Esophageal cancer is the eighth most common cancer
and the sixth leading reason for cancer-related mortality
worldwide [1-4]. Despite therapeutic advances over last
two decades, esophageal cancer still has a very poor
prognosis, and the 5-year survival rates have been re-
ported to be below 20% [4,5].
Squamous cell carcinomas make up the majority of
esophageal cancers worldwide with a very high incidence
in the Middle East and Southern Asia [6,7]. In recent
years, the incidence of esophageal adenocarcinomas has
increased considerably in Australia, Western Europe and
the United States [1,8,9].
Surgical resection has been established as the main
treatment option for locally limited cancer stages, and
several surgical approaches are available for treatment
depending on tumor localization and extent [10,11]. In
loco-regionally advanced but resectable stages, neoadju-
vant chemoradiation followed by surgery results in bet-
ter outcomes compared to surgery alone. However, none
of the randomized trials has shown superiority of the trimo-
dal tatment compared to definitive radiochemotherapy
considering the overall survival of partients [12,13].
Further challenging the necessity for surgery is the
finding that almost 50% of affected patients are not
amendable at all to major surgery for technical, functional
or medical reasons at the time of diagnosis [14]. In those
patients, definitive chemo-radiation therapy is the estab-
lished treatment of choice. Early trials have shown
beneficial effects compared to radiotherapy alone [15,16],
and definite chemo-radiotherapy has been shown in smaller
studies to be comparable to surgery in patients
with non-metastatic disease [17,18]. Chemotherapeutic
drugs cisplatin and 5-fluorouracil have been most
commonly used in studies examining the effects of de-
finitive chemo-radiotherapy in esophageal cancer [1],
while the addition of targeted agent cetuximab to the
chemo-radiation regime has shown an adverse out-
come and increase in treatment-related toxicities com-
pared to chemo-radiotherapy alone [19].
Dose considerations for esophageal radiotherapy have
been based mainly on the results of the RTOG 94–05
trial, in which radiation doses of 50.4 Gy and 64.8 Gy
were compared using non-intensity modulated radiation
therapy [20,21]. Somewhat surprisingly this trial did not
show a difference in either loco-regional control or other
endpoints including quality of life. Therefore the lower
dose of 50.4 Gy has been established as the standard
dose for esophageal chemo-radiotherapy. However, the
still high rate of loco-regional failures indicates the need
for further improvement of the local therapy component.
Because the radiation techniques have considerably im-
proved with the introduction of IMRT, we hypothesized
that higher radiation doses delivered with IMRT couldimprove the clinical outcome. Thus we started to treat
patients with locally advanced esophageal cancer who
were candidates for definitive combined radio chemo-
therapy with increased dose intensity-modulated radio-
therapy using an integrated boost concept.
Patients and methods
Patient characteristics
27 consecutive patients were treated with increased dose
intensity-modulated radiation therapy as part of defini-
tive treatment of esophageal cancer at the German
Cancer Research Center (DKFZ) between 2005 and
2009, and were included in this analysis. Median age was
63 years (range 42 – 79 years) and 81% of patients were
male (22 patients). Histological confirmation of esopha-
geal cancer was obtained prior to treatment for all pa-
tients included in this analysis, and squamous cell
carcinoma was the dominant histology (81%). 93% of pa-
tients suffered from T3 or T4 tumors and/or N1 disease.
Detailed patient characteristics are listed in Table 1.
Treatment application
Initial workup included at least clinical and laboratory
examinations, endoscopy with biopsy, computed tomog-
raphy of the primary tumor region and regional lymph
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according to the 6th edition of the UICC TNM classifica-
tion. In general, the GTV consisted of the primary tumor
and involved lymph nodes as visible on contrast-enhanced
CT. Primary tumor volume delineation was further sup-
ported by clips or FDG-PET information (Figure 1). Nodal
GTV delineation was supported by available FDG-PET
information. A margin of 1-2 cm was added in axial and
2–3 cm in longitudinal direction to the primary tumor to
directly construct the boost volume (PTV1). The nodal
volume (CTV2) included the regional lymph node regions
within 4-5 cm in longitudinal direction from the edge of
the primary tumor or at least 2-3 cm from the edge of the
last involved lymph node. A margin of 0.5 cm was
added to construct the PTV2. Margins could be re-
duced near critical organs at the discretion of the treat-
ing radiation oncologists.
Treatment delivery was performed by intensity-
modulated radiation therapy (IMRT) using the step-and-
shoot technique in all patients. Inverse treatment-planning
was performed after immobilization of the patients in a vac-
uum pillow using the KonRad and VIRTOUS softwares de-
veloped at the German Cancer Research Center (DKFZ).
Regional lymph node areas were irradiated to a median
dose of 50.4 Gy in 28 fractions (range 14.4 to 52.2 Gy,
single dose 1.8 Gy). The boost volume was covered with a




Figure 1 Example pictures for dose distributions. Sample pictures show
PET/CT-based treatment planning. Red lines define boost volumes and pinpatients (78%) an integrated boost concept with slightly in-
creased single doses of 2 to 2.14 Gy up to total doses of 56-
60 Gy was used, while the remaining 6 patients received a
sequential boost (range 9-10.8 Gy). 26 of the 27 patients
completed radiation therapy with total doses of ≥ 56 Gy to
the boost area. During treatment, image guidance with a
CT on rails was performed at least once per week.
All patients were scheduled for concomitant systemic
therapy. 26 of the 27 patients (96%) received concurrent
systemic therapy, usually consisting of two courses cis-
platin (20 mg/m2 BSA) and 5-fluorouracil (1000 mg/m2
BSA) on days 1 to 5 and days 21 to 25. Additionally, 17
patients (63%) also received adjuvant platinum-based
chemotherapy.
Clinical follow-up examinations and quality of life
questionnaire
Regular follow up visits at our institution or the refer-
ring center included at least clinical examination, en-
doscopy and CT of the primary tumor and regional
nodal regions. In case of clinical evidence for loco-
regional recurrence or distant spread, additional tests
or imaging modalities were performed to confirm or
exclude disease progression at the discretion of the
treating physician. Toxicity was scored according to
CTCAE V3.0. In case of missing follow-up examina-
tions, data was completed by calling the patient or theing dose distributions as obtained from clip-based (upper panel) or
k lines planning target volumes.
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from the first day of radiation treatment until the last
follow up information or until death. Loco-regional
control was defined as absence of disease progression
in the primary tumor region or regional lymph nodes.
In patients without further assessment of loco-regional
control, e.g. after development of distant spread, the
date of the last information about the loco-regional
status was used for calculation. Progression-free sur-
vival (PFS) was defined as absence of disease progres-
sion at any site or death of any cause. No subgroup
analyses were performed due to the limited number of
patients and events.
To better assess the quality of life of the patients
undergoing combined radiochemotherapy we asked
the patients to answer the EORTC questionnaire for
the combined assessment of the quality of life (HRQL)
for oesophageal cancer (QLQ-OG25) and specific
questions from QLQ-H&N35 suitable for cervical or
higher oesophageal cancer along with questions from
QLQ-C30 addressing general cancer and therapy is-
sues. QLQ-OG25 has six scales, dysphagia, eating re-
strictions, reflux, odynophagia, pain and anxiety.
The study is in compliance with the Declaration of
Helsinki (Sixth Revision, 2008). Furthermore the study
was approved by the Independent Ethics Committee of
the Medical Faculty of the University of Heidelberg,
Heidelberg, Germany (Ref. Nr.: S-490/2010).Time













Figure 2 Kaplan-Meier curve for loco-regional control probability.Statistics
Actuarial survival and loco-regional control were calcu-
lated using the Kaplan-Meier method and the QLQ
questionnaire was analyzed using descriptive statistics,
both using the Statistica software package (Statsoft 6.0).
Results
Local control and survival
Median follow-up was 26 months (range 1 – 65 months)
for the entire cohort and 34 months for surviving pa-
tients. Loco-regional recurrence was observed in 10 pa-
tients after a median time of 12 months, translating into
estimated 1-, 2- and 3-year loco-regional control rates of
77%, 65% and 48% (Figure 2). 7 patients developed distant
failures with a median time to occurrence of 8 months. 5 of
them (71%) were located in the lung, while 2 (29%) patients
suffered from liver metastases. The resulting estimated 1-,
2- and 3-year progression-free survival rates were 58%, 48%
and 36% (Figure 3). Median overall survival was not
reached. Estimated overall survival rates at 1, 2 and 3, years
were 82%, 61% and 56% (Figure 4).
Toxicity
Overall tolerance of definitive chemo-radiation was high.
Radiotherapy was applied up to the planned dose in all
except one patient (96%). 26 patients (96%) started con-
comitant systemic therapy and 21 patients (81%) re-
ceived ≥ 80% of the scheduled cycles. [months]
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Figure 3 Kaplan-Meier curve depicting progression-free survival probability.
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Figure 4 Kaplan-Meier curve for overall survival probability.
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(52%). Hematological toxicities were most commonly
observed with 4 patients developing grade 3 and 3 pa-
tients developing grade 4 leukopenia, 2 patients showing
grade 4 thrombocytopenia and 1 patient suffering from
grade 3 anemia. Therapy-related grade 3 or 4 dysphagia
requiring PEG tube feeding was observed in 5 patients
(19%). Acute skin and mucosal toxicities were uncom-
mon with 1 patient developing an acneiforme rash and 2
patients reporting painful oral ulcers during treatment.
Severe late toxicities were detected in 6 patients (22%).
Dysphagia was most commonly observed with 5 patients
(19%) suffering from grade 3/4 esophageal toxicity due
to ulcerations or strictures. Symptoms subsided in all
but one patient after treatment with proton pump inhibi-
tors or repeated dilatation. One patient required tracheal
stenting after treatment due to the development of a
tracheo-esophageal fistula. Severe late radiation-associated
toxicities affecting skin, lung and heart were rare, with one
patient suffering from a myocardial infarction and one from
symptomatic pneumonitis.
QLQ questionnaire information suitable for analysis
was available in 16 patients. Surprisingly, the patients re-
ported that general effects of the disease or therapy were
subjectively absent in almost 2/3 (62%) of patients at
3 months after radiotherapy end, 22% reported that
‚some effects were present’, 10% reported ‚significant ef-
fects’ and only 5% estimated the symptoms or other
problems as “very significant”.
With respect to dysphagia and food intake, at 3 months
after the end of radiotherapy 13% of patients used a
feeding tube, but all together only 20% reported ‘signifi-
cant’ eating restrictions with solid food, while soft food
and fluids could be swallowed well in general. 60% had
no heart burn at all, while 40% had mild heart burn.
Mild reflux was only present in ~15%. In the majority
(>75%) of patients. body weight was stable or increasing.
80% of patients did not need any pain medication. With
respect to a general health 57% reported ‘not at all’, 26% re-
ported ‘mild’, 9% ‘significant’, and 9% very significant restric-
tions on the quality of life. The mean self-evaluated health
condition was 4.7 (almost ‘good’) on a scale from 1 (very
sick) to 7 (excellent).
Discussion
In this study, we present encouraging survival and tox-
icity data of esophageal patients treated with definitive
high-dose chemo-radiotherapy. In our cohort of 27 con-
secutively treated patients, estimated overall survival
rates at 1, 2 and 3, years were 82%, 61% and 56%, re-
spectively, comparing well with other recent studies. A
recent meta-analysis including 6 major studies with a
total of 929 patients reported 2-year overall survival
rates between 35 and 58% using definitive chemo-radiotherapy [22]. Another trial investigating 287 pa-
tients showed 2-year survival rates of 29% for patients
suffering from esophageal squamous cell carcinoma and
19% for those with adenocarcinoma [23].
For a long time, dose considerations for esophageal
chemo-radiotherapy have been based on the findings of
the RTOG 94–05 study that compared an established
dose regime of 50.4 Gy with high-dose irradiation using
64.8 Gy [21,24]. In this study based on conventional 2D
radiotherapy planning, higher doses did not offer any
benefit regarding loco-regional control or survival while
being associated with a higher percentage of treatment-
related mortality. Quality of life analysis of the RTOG
94–05 study did not show a significant difference be-
tween 50.4 Gy and 64.8 Gy at 8 and 12 months after
treatment [20]. Based on these findings, the recommended
standard dose for esophageal cancer is 50.4 Gy [1,21]. In
contrast to the results presented in the RTOG 94–05
study, a meta-analysis published by Geh et al. sug-
gested a dose–response relationship between increased
radiation doses and pathological complete remission,
warranting dose escalation studies in esophageal can-
cer [25].
The advent of highly conformal radiotherapy tech-
niques and especially IMRT has generally enabled physi-
cians to apply higher tumor doses without a significant
increase in the doses absorbed by the surrounding nor-
mal tissue. A planning study using IMRT in esophageal
cancer patients showed that dose escalation from 45 to
54 Gy was possible without significantly increasing nor-
mal tissue doses [26]. Additional data suggest that rota-
tional IMRT techniques are able to further decrease
doses to organs at risk compared to standard step-and-
shoot IMRT [27,28]. Another planning study in esopha-
geal cancer comparing 2D radiotherapy plans using
50.4 Gy and IMRT plans using 64.8 Gy demonstrated a
significant reduction of normal tissue dosage in the
high-dose IMRT plans despite a 14 Gy increase in the
tumor dose [29].
Due to esophageal movement and the risk of micro-
scopic spread around the macroscopic tumor, large
safety margins are commonly used as part of the clinical
(CTV) and planning (PTV) target volumes. The RTOG
94-05 study based radiotherapy planning on 2D radio-
graphs and recommended safety margins up to 5 cm.
The advent of modern imaging modalities in defining
target volumes in esophageal cancer patients has been
subject to intense research as it holds the potential of
more closely delineating target structures and decreasing
PTV margins. Based on endoscopic ultrasound and
PET/CT, planning studies using esophageal cancer data
recommended 3 cm margins [21,30]. In our dataset,
treatment planning was based on initial CT scans and ei-
ther 18 F-fluorodeoxyglucose PET/CT or endoscopic clip
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has been investigated as a means of delineating esopha-
geal tumors and detecting metastatic lymph nodes for
incorporation into the radiation treatment volume
[31-33]. In a study published by Muijs et al. beneficial ef-
fects of PET/CT-based radiotherapy planning were dem-
onstrated regarding target dose coverage and normal
tissue complication probabilities [34]. In another study
by Gondi et al. the availability of PET/CT information
during treatment planning resulted in decreased GTV
volumes in 63% of patients [35]. It is therefore conceiv-
able that PET/CT-based radiotherapy planning may have
the potential of further reducing safety margins, enabling
higher treatment doses to the tumor and less normal tis-
sue toxicities. However, further studies establishing the
role of PET/CT in defining esophageal treatment vol-
umes are warranted. Similarly, clip markings of the
upper and lower end of the macroscopic tumor have
shown benefits regarding target volume definition and
may aid in applying increased treatment doses [36].
Additionally, image guidance has been examined as a
means of increasing treatment precision and hence
allowing dose escalation. Han et al. demonstrated signifi-
cant inter-fractional setup errors for esophageal radio-
therapy without daily image guidance [37]. In this
setting, cone beam CT scans have been shown to be su-
perior to portal imaging [38]. All of our patients received
regular CT-based image guidance and repositioning
prior to radiotherapy.
Treatment-related acute and late toxicities in our co-
hort of esophageal cancer patients were moderate. While
about 50% of patients were observed to suffer from at
least one acute grade 3 or 4 side effect, less than one
quarter developed severe late toxicities. Hematological
toxicities and dysphagia were the most common severe
side effects noted in our patient group. IMRT treatment
of esophageal cancer has previously been shown to re-
sult in reduced salivary gland toxicity and dysphagia, but
increased rates of in-field toxicity, especially esophageal
strictures [39]. Emami et al. reported a calculated 5%
risk of esophageal stricture or perforation when 60 Gy
were applied to more than one third of the esophagus
[40]. Correspondingly, esophageal strictures were the
most common late side effects observed in our patient
group treated with high dose IMRT and concerned al-
most 20% of patients. However, these side effects are
well amenable to treatment [41], and we found them to
subside in all but one patient. Dose escalation studies
using higher radiation doses up to 72 Gy incorporating
endoluminal brachytherapy have shown even higher per-
centages of local side effects like esophagitis, ulcerations
and strictures [42]. Other studies have evaluated out-of-
field toxicities, especially lung and heart toxicities after
esophageal radiotherapy and demonstrated beneficialeffects of IMRT compared to 3D conformal treatments
[43,44]. However, due to the increased number of beams
used for IMRT, several studies have found higher levels
of pulmonary low-dose areas receiving less than 7 Gy
(reviewed in [45]). Furthermore, high rates of hematological
toxicity after esophageal chemo-radiotherapy with doses ex-
ceeding 60 Gy have been reported, but effects have often
been attributed to concurrent systemic treatment [46,47].
Interestingly, the questionnaire self-evaluation of patients
after 3 months after the end of radiotherapy based on
EORTC QLQs (QLQ-OG25, QLQ-H&N35 and QLQ-C30)
focusing on dysphagia, eating restrictions, reflux, pain and
anxiety revealed very encouraging results [8]. The subject-
ive self-evaluation showed that ~50% of patients had no
disease related symptoms, 25% encountered only mild
problems and only 10% had significant or very significant
restrictions of the quality of life.
Our study has limitations such as the small patient
number and short follow-up period. Nevertheless, we dem-
onstrated that intensity-modulated radiotherapy using in-
creased doses up to 60 Gy via an integrated boost is
feasible for the definitive treatment of esophageal cancer
and can safely be applied in combination with concurrent
systemic therapy. Our data also demonstrate encouraging
results in terms of local control and survival with low acute
and late side effects along with high satisfaction rates in
self-evaluations. Taken together, our data may add to the
literature that challenges the necessity for surgery in
patients with locally advanced esophageal cancer. Fur-
thermore, prospective studies investigating new radi-
ation strategies with chemotherapy in larger cohorts of
esophageal cancer patients are warranted.
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